There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on VBI Vaccines (VBIV) and Endologix Inc (ELGX) with bullish sentiments.
VBI Vaccines (VBIV)
In a report issued on December 6, Kumaraguru Raja from Brookline Capital Markets maintained a Buy rating on VBI Vaccines, with a price target of $10. The company’s shares closed on Friday at $1.49, close to its 52-week low of $1.45.
Raja commented:
“VBI Vaccines has entered into a license and collaboration agreement with the development of a therapeutic for Hepatitis-B infection using VBI Vaccines’ recombinant, protein-based immunotherapeutic VBI-2601. Brii is a China-based company and would now be eligible to develop and commercialize the planned therapeutic in and Taiwan. VBI has received an upfront payment of $11M ($4M upfront and $7M in equity investment priced at $3.05/share). It should also receive another $117.5M in potential milestone payments, and potential double- digit royalties from sales in the licensed territory.”
According to TipRanks.com, Raja is a 1-star analyst with an average return of -6.7% and a 35.1% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Corbus Pharmaceuticals, and Acer Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VBI Vaccines with a $10 average price target.
See today’s analyst top recommended stocks >>
Endologix Inc (ELGX)
BTIG analyst Sean Lavin reiterated a Buy rating on Endologix Inc on December 6 and set a price target of $4. The company’s shares closed on Friday at $0.71, close to its 52-week low of $0.67.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 9.0% and a 56.6% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
Endologix Inc has an analyst consensus of Moderate Buy, with a price target consensus of $2.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
